Skip to content

Multimedia-based Hormonal Therapy Information Program for Patients With Prostate Cancer

Development and Evaluation of the Effectiveness of a Multimedia-based Hormonal Therapy Information Program for Patients With Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04693910
Enrollment
80
Registered
2021-01-05
Start date
2019-05-13
Completion date
2021-01-31
Last updated
2021-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Neoplasms

Keywords

prostate cancer, hormonal therapy, multimedia, self-efficacy, positive thinking

Brief summary

This study takes place in the Divisions of Urology. Patients who have only received hormonal therapy will be enrolled. Patients will be randomly sorted into an experimental group and a control group after completing a pretest questionnaire. The experimental group will receive the the multimedia hormone therapy information program once per week for 6 consecutive weeks, while the control group will receive routine care. The follow-up data collections will be completed at 8 and 12 weeks after the pretest. For quantitative measurement, the main variables will be social support, self-efficacy, quality of life, and positive thinking.

Detailed description

This study takes place in the Divisions of Urology at Chang Gung Memorial Hospitals. Patients who have only received hormonal therapy will be enrolled. With reference to past research findings, self-efficacy theory, and experts' advice, a multimedia hormone therapy information program was developed. The multimedia hormone therapy information program covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue. A pilot study will be conducted to check the feasibility of intervention study design and the effectiveness of the program will be tested. Patients will be randomly sorted into an experimental group (multimedia information group, n = 36 to 40) and a control group (routine care group, n = 36 to 40) after completing a pretest questionnaire. The experimental group will receive the multimedia information intervention once per week for 6 consecutive weeks, while the control group will receive routine care. The follow-up data collections will be completed at 8 and 12 weeks after the pretest. For quantitative measurement, the main variables will be social support, self-efficacy, quality of life, positive thinking, and satisfaction with program. Generalized Estimating Equations (GEEs) will be used to o analyze data.

Interventions

OTHERMultimedia-Based Hormone Therapy Information Program

The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.

Sponsors

Ministry of Science and Technology, Taiwan
CollaboratorOTHER_GOV
Chang Gung Memorial Hospital
CollaboratorOTHER
National Taipei University of Nursing and Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
MALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. patients with prostate cancer who were receiving hormonal therapy 2. patients were at least 20 years old 3. patients were ability to communicate in Chinese or Taiwanese 4. the married partner agrees to study together, or the single patient has a cohabitation partner who agrees to study together. 5. patients or family have a smart phone or tablet and can connect to the Internet.

Exclusion criteria

1. having a history of other cancers 2. unknown diagnosis of prostate cancer or unknown disease status 3. patients who received chemotherapy, radiotherapy, radical prostatectomy or other treatments for prostate cancer in the past 4. having history of mental disorder, e.g., phobia, obsessive-compulsive disorder, generalized anxiety, , major depression, mania, manic-depressive psychosis, or dementia 5. the score of Eastern Cooperative Oncology Group performance is ≧ 2

Design outcomes

Primary

MeasureTime frameDescription
Functional Assessment of Cancer Therapy-Prostate (FACT-P)pretestA total of 39 items, including five subdimensions, namely, physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate cancer subscales. A 5-point scoring method was adopted. Higher scores indicate higher quality of life
The Positive Thinking ScalepretestA total of 18 items, including two subscales of personal satisfaction and goal pursuit. A five-point (1-5) scoring method was used. Higher scores indicate a higher level of positive thinking
The Hormonal Dimension of The Expanded Prostate Cancer Index Compositepretest11 items were used, the score of each item ranges from 0 to 100 points. Higher scores indicate fewer hormonal symptoms.

Secondary

MeasureTime frameDescription
The General Self-Efficacy ScalepretestThe total scale contains 10 items and a 4-point (1-4) scoring method was adopted. Higher scores indicate higher self-efficacy
The Social Support ScalepretestA total of 16 items, including four sub-scales of emotional, informational, appraisal, and instrumental support. A 4-point scoring method (0-3) was used. Higher scores indicate stronger support.

Other

MeasureTime frameDescription
Basic and disease information list 13pretestHistory of chronic disease
Basic and disease information list 14pretestLiving status
Basic and disease information list 15pretestHeight in centimetre
Basic and disease information list 16pretestBody Mass Index in kg/m2 will be computed from height and body weight
Basic and disease information list 17pretestBody weight in kilograms
Basic and disease information list 18pretestWaist circumference in centimetre
Basic and disease information list 19pretestSerum Prostatic Specific Antigen level
Basic and disease information list 208 weeks after the pretestSerum Prostatic Specific Antigen level
Basic and disease information list 2112 weeks after the pretestSerum Prostatic Specific Antigen level
Basic and disease information list 1pretestAge
Basic and disease information list 8pretestJoin a support group
Basic and disease information list 3pretestMarital status
Basic and disease information list 4pretestReligion
Basic and disease information list 5pretestOccupation
Basic and disease information list 6pretestAnnual family income (NTD)
Basic and disease information list 7pretestNumber of children
Basic and disease information list 22pretestPerceived health status. A 11-point (0-100) scoring method was used. Higher scores indicate better health condition.
Basic and disease information list 238 weeks after the pretestPerceived health status. A 11-point (0-100) scoring method was used. Higher scores indicate better health condition.
Basic and disease information list 2412 weeks after the pretestPerceived health status. A 11-point (0-100) scoring method was used. Higher scores indicate better health condition.
List of satisfaction with Program8 weeks after the pretestFive items were self-designed to understand the satisfaction of men in the experimental group. A 11-point (0-100) scoring method was used. Higher scores indicate higher satisfaction.
Basic and disease information list 2pretestEducation level
Basic and disease information list 9pretestTime since diagnosis (months)
Basic and disease information list 10pretestTumor-node-metastasis Cancer stage
Basic and disease information list 11pretestGleason score
Basic and disease information list 12pretestTreatment

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026